Blog

Unveiling the Mysteries of the Mind: A Landmark Event in New Orleans

Feb 14 • 3 min read

From February 16th to 18th, the vibrant city of New Orleans will play host to one of the most anticipated events in the field of psychology. It’s the second annual International Society for Research on Psychedelics conference! This gathering promises to be a melting pot of ideas, showcasing the latest advancements and innovative research in…

New Mexico Takes Bold Steps Towards Psilocybin Therapy Research

Feb 14 • 4 min read

In a remarkable show of bipartisan unity, a New Mexico Senate committee has recently cast a unanimous vote in favor of a resolution aimed at delving into the therapeutic potential of psilocybin mushrooms. This initiative marks a significant stride towards understanding and potentially integrating this psychedelic into therapeutic settings. Spearheaded by Senate Minority Whip Craig…

Cybin Reports Third Quarter Financial Results and Recent Business Highlights

Feb 14 • 7 min read

TORONTO, February 14, 2024–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company“), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, today reported unaudited financial results for its third quarter ended December 31, 2023, and recent business highlights. “During the past three months, we have…

A Doctor is Suing the DEA To Treat Terminally Ill Patients with Psilocybin

Feb 12 • 3 min read

Dr. Sunil Aggarwal, alongside the Advanced Integrative Medical Science Institute (AIMS) he helped establish, is challenging the Drug Enforcement Administration (DEA) in court. Their lawsuit arises from the DEA’s refusal to permit the use of psilocybin for treating patients facing the end stages of their lives, despite Washington state’s “Right-to-Try” law, which allows for the…

The FDA Accepts MDMA for PTSD Therapy’s New Drug Application

Feb 12 • 2 min read

The U.S. Food and Drug Administration (FDA) has recently accepted a groundbreaking New Drug Application (NDA) submitted by Lykos Therapeutics for MDMA-assisted therapy in the treatment of Post-Traumatic Stress Disorder (PTSD). This pivotal moment signifies a crucial step forward in the potential adoption of psychedelic-assisted treatments within conventional medical practices. Originating from the Multidisciplinary Association…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543